Autolus Therapeutics plc Interest Expense
Autolus Therapeutics plc (AUTL) reported Interest Expense of -$2.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-11
- Autolus Therapeutics plc interest expense for the quarter ending 2026-06-30 was -$2.67M.
- Autolus Therapeutics plc interest expense for the quarter ending 2026-03-31 was $11.12M, a 9.67% increase year-over-year.
- Autolus Therapeutics plc interest expense for the quarter ending 2025-12-31 was $22.84M.
- Autolus Therapeutics plc interest expense for the quarter ending 2025-09-30 was $10.52M, a 1.55% decline year-over-year.
- Autolus Therapeutics plc interest expense for fiscal 2025 was $36.67M, a 294.56% increase from fiscal 2024.
- Autolus Therapeutics plc interest expense for fiscal 2024 was $9.29M, a 79.38% decline from fiscal 2023.
- Autolus Therapeutics plc interest expense for fiscal 2023 was $45.07M, a 406.09% increase from fiscal 2022.
- Autolus Therapeutics plc interest expense for fiscal 2022 was $8.90M, a 705.88% increase from fiscal 2021.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.67M 10-Q · filed 2026-08-11 | $8.45M 10-Q · filed 2026-08-11 | $31.29M derived: sum of 3 quarters · filed 2026-08-11 | $41.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $11.12M 10-Q · filed 2026-05-14 | $33.96M derived: sum of 2 quarters · filed 2026-05-14 | $44.48M derived: sum of 3 quarters · filed 2026-05-14 | $37.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $22.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $33.36M derived: sum of 2 quarters · filed 2026-03-27 | $26.53M derived: sum of 3 quarters · filed 2026-08-11 | $36.67M 10-K · filed 2026-03-27 |
| 2025-09-30 | $10.52M 10-Q · filed 2025-11-12 | $3.69M derived: sum of 2 quarters · filed 2026-08-11 | $13.83M 10-Q · filed 2025-11-12 | -$17.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$6.83M 10-Q · filed 2026-08-11 | $3.31M 10-Q · filed 2026-08-11 | -$27.52M derived: sum of 3 quarters · filed 2026-08-11 | -$16.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $10.14M 10-Q · filed 2026-05-14 | -$20.69M derived: sum of 2 quarters · filed 2026-05-14 | -$10.01M derived: sum of 3 quarters · filed 2026-05-14 | $168.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$30.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$20.15M derived: sum of 2 quarters · filed 2026-03-27 | -$9.97M derived: sum of 3 quarters · filed 2026-03-27 | $9.29M 10-K · filed 2026-03-27 |
| 2024-09-30 | $10.69M 10-Q · filed 2025-11-12 | $20.86M derived: sum of 2 quarters · filed 2025-11-12 | $40.13M 10-Q · filed 2025-11-12 | $70.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $10.17M 10-Q · filed 2025-08-12 | $29.44M 10-Q · filed 2025-08-12 | $59.57M derived: sum of 3 quarters · filed 2025-08-12 | $64.58M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $19.27M 10-Q · filed 2025-05-08 | $49.40M derived: sum of 2 quarters · filed 2025-05-08 | $54.41M derived: sum of 3 quarters · filed 2025-05-08 | $59.43M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $30.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $35.14M derived: sum of 2 quarters · filed 2025-03-20 | $40.16M derived: sum of 3 quarters · filed 2025-03-20 | $45.07M 10-K · filed 2025-03-20 |
| 2023-09-30 | $5.01M 10-Q · filed 2024-11-12 | $10.03M derived: sum of 2 quarters · filed 2024-11-12 | $14.94M 10-Q · filed 2024-11-12 | $18.40M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $5.02M 10-Q · filed 2024-08-08 | $9.93M 10-Q · filed 2024-08-08 | $13.38M derived: sum of 3 quarters · filed 2024-08-08 | $15.23M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.91M 10-Q · filed 2024-05-17 | $8.36M derived: sum of 2 quarters · filed 2024-05-17 | $10.21M derived: sum of 3 quarters · filed 2024-05-17 | $12.02M derived: sum of 4 quarters · filed 2024-05-17 |
| 2022-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $5.31M derived: sum of 2 quarters · filed 2024-03-21 | $7.12M derived: sum of 3 quarters · filed 2024-03-21 | $8.90M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.85M 10-K · filed 2024-03-21 | $3.66M derived: sum of 2 quarters · filed 2024-03-21 | $5.45M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $1.81M 10-K · filed 2024-03-21 | $3.60M derived: sum of 2 quarters · filed 2024-03-21 | ||
| 2022-03-31 | $1.79M 10-K · filed 2024-03-21 | |||
| 2021-12-31 | $1.10M 10-K · filed 2024-03-21 | |||
| 2020-12-31 | $0.00 20-F · filed 2023-03-07 | |||
| 2019-12-31 | $0.00 20-F · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |